Okamoto Akiko, Okamoto Teppei, Ichiyama Takaki, Fukushima Takafumi, Omizo Sosuke, Asanuma Himawari, Sato Hiroyuki, Sakurai Hisashi, Yoneyama Anna, Yoneyama Fumiya, Ishii Noritaka, Oishi Takuya, Tanaka Ryuma, Miura Hikari, Hamaya Tomoko, Kodama Hirotake, Fujita Naoki, Murasawa Hiromi, Yamamoto Hayato, Imai Atsushi, Saitoh Hisao, Hatakeyama Shingo, Ohyama Chikara, Suzuki Tadashi
Department of Urology, Oyokyo Kidney Research Institute Hirosaki Hospital, Hirosaki, Japan.
Department of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Ren Fail. 2025 Dec;47(1):2512053. doi: 10.1080/0886022X.2025.2512053. Epub 2025 Jun 2.
The long-term cardiovascular (CVD) and mortality risk associated with mild COVID-19 infections in patients on hemodialysis (HD) during the post-Omicron era remains unclear. This study evaluates clinical outcomes in patients on HD following Omicron infection.
This retrospective observational study included 462 patients from a single center. All mild COVID-19 cases occurred after January 2022. The first analysis compared patients with prior mild COVID-19 (COVID-19 history [+], = 63) to those never infected including the observational period (COVID-19 infection [-], = 286). The second analysis included 392 patients without prior infection, comparing those who acquired mild COVID-19 during follow-up (COVID-19 infection [+]) with those in the COVID-19 infection [-] group. The primary outcome was CVD events. Multivariate analyses assessed COVID-19 infections's impact on clinical outcomes.
After 761 days, 100 CVD events including 51 cardiovascular deaths and 58 non-CVD deaths occurred. The CVD risk did not significantly differ between the COVID-19 history (+) and infection (-) groups (Hazard ration [HR]: 0.50, 95% confidence interval [CI]: 0.25-1.01, = .054) as well as non-CVD mortality. In the second analysis, patients with newly acquired COVID-19 did not exhibit a significantly increased risk of CVD (HR: 0.55, 95% CI: 0.25-1.19, = .132) or non-CVD mortality.
Mild COVID-19 infections does not significantly increase long-term CVD and mortality risk in patients on HD in the post-Omicron era.
在奥密克戎时代之后，血液透析（HD）患者中轻度新冠病毒感染（COVID-19）相关的长期心血管疾病（CVD）和死亡风险仍不明确。本研究评估了奥密克戎感染后HD患者的临床结局。
这项回顾性观察性研究纳入了来自单一中心的462例患者。所有轻度COVID-19病例均发生在2022年1月之后。第一次分析将既往有轻度COVID-19的患者（COVID-19病史[+]，n = 63）与未感染患者（包括观察期）（COVID-19感染[-]，n = 286）进行了比较。第二次分析纳入了392例无既往感染的患者，将随访期间感染轻度COVID-19的患者（COVID-19感染[+]）与COVID-19感染[-]组的患者进行了比较。主要结局是CVD事件。多变量分析评估了COVID-19感染对临床结局的影响。
761天后，发生了100例CVD事件，包括51例心血管死亡和58例非CVD死亡。COVID-19病史（+）组和感染（-）组之间的CVD风险以及非CVD死亡率没有显著差异（风险比[HR]：0.50，95%置信区间[CI]：0.25 - 1.01，P = 0.054）。在第二次分析中，新感染COVID-19的患者CVD风险（HR：0.55，95% CI：0.25 - 1.19，P = 0.132）或非CVD死亡率没有显著增加。
在奥密克戎时代之后，轻度COVID-19感染不会显著增加HD患者的长期CVD和死亡风险。
